Several approaches to obtaining parenteral formulations for water-insoluble or poorly soluble drugs have been reported and dispersed systems for drug delivery such as emulsions, liposomes and nanospheres are improving all the time.
mean particle size of lipo-KW-3902 was about 100 nm.
KW-3902 Solution KW-3902 (50 mg) was dissolved in 5 ml of dimethyl sulfoxide. An aliquot of this solution (200 ml) was mixed with 200 ml of 1 N NaOH, and then diluted to 20 ml with saline (KW-3902: 0.1 mg/ml).
Electron Microscopy Negative-stain electron microscopy was performed according to the method of Magin and Weinstein. 32) Carbon-coated copper grids (150-B mesh) were purchased from Okenshoji Co., Ltd. (Tokyo, Japan). A drop of 2% ammonium molybdate was placed on the grid and removed after 8 min. The grid was air dried and then examined by electron microscopy (Hitachi H-7000, 75 kV voltage).
Animal Experiments Male Sprague-Dawley rats, weighing 200-300 g, (Nihon SLC Co., Ltd., Hamamatsu, Japan) were used throughout this experiment. A group of three was randomly selected from the population. The rats were fasted overnight before use, but allowed free access to water, and were fixed in a dorsal position under urethane anesthesia (1 g/kg, i.p.). Each formulation containing KW-3902 was injected into the tail vein of rats at a dose of 0.1 and 1 mg/kg body weight. At appropriate intervals after injection, blood was collected from the abdominal aorta and rats were sacrificed. The lung, liver, spleen, kidney and heart were excised, rinsed with saline, weighed, and subjected to assay.
Analysis of KW-3902 and M1 in Plasma Blood samples were heparinized, and after centrifugation (3000 rpm-15 min), plasma was obtained. An aliquot of saturated sodium hydrogen carbonate solution (0.5 ml) and 0.1 ml of internal standard (I.S.) solution (KF16082 was used for KW-3902 assay and KF18627 for M1 assay, Fig. 1 ) were added to 0.5 ml of plasma and then the mixture was extracted with 4 ml of diethyl ether by mixing for 10 min. Insoluble proteins were removed from the solution by centrifugation at 3000 rpm for 5 min. After the solvent layer was dried in vacuo, the residue was resolved with methanol and then KW-3902 and M1 were detected by HPLC.
Analysis of KW-3902 in Organs Collected organs were homogenized with distilled water. To an aliquot of the homogenate (500 ml), first 500 ml of saturated sodium hydrogen carbonate solution and then 0.1 ml of I.S. solution (KF16082 was used for KW-3902 assay and KF18627 for M1 assay) and 5 ml of diethyl ether were added. After 10 min of shaking, the mixture was centrifuged at 3000 rpm for 10 min. The solvent layers were collected and dried in vacuo. The residue was resolved with methanol and KW-3902 and M1 were detected by HPLC.
HPLC Analysis KW-3902 was determined by HPLC on a YMC-Pack AM-312 column (5 mm, 150ϫ6 mm, YMC Co., Ltd., Kyoto, Japan). The mobile phase consisted of a mixture of 50 mM ammonium acetate and acetonitrile at 35 : 65 (v/v) delivered at a flow rate of 1.0 ml/min. A UV detector operated at 276 nm was used to detect and quantitate KW-3902. M1 was determined by HPLC using the same column. The mobile phase consisted of a mixture of 50 mM acetate buffer (pH 5), acetonitrile and methanol at 36 : 14 : 50 (v/v/v) delivered at a flow rate of 1.0 ml/min. A UV detector operated at 276 nm was used to detect and quantitate M1. Calibration curves were constructed by plotting the peak area of the analyte to I.S. against the concentration of analyte. The data were fitted to least squares linear regression and the linearities of the standard curves were found in the range from 2 to 1000 ng/ml (rϾ0.995).
Data Analysis The pharmacokineic parameters in rats were calculated from the individual analyte blood concentration-time curve after intravenous injection by a non-compartment model using the pharmacokinetics software package WinNonlin TM Ver. 3.1 (Pharsight Co., Mountain View, CA, U.S.A.). The area under the plasma concentration-time curves (AUC 0-ϱ ) were calculated using the trapezoidal rule and by extrapolating the time to infinity using the elimination rate constant (k el ) values. The elimination half-life (T 1/2 ) was calculated by dividing 0.693 by k el . The apparent total body clearance (CL) was calculated from Dose/AUC 0-ϱ . The mean residence time (MRT) was calculated as AUMC/AUC, AUMC meaning the area under the first moment curve. The apparent volume of distribution at steady-state (V dss ) was calculated as CL · MRT. The metabolic ratio (MR) was calculated as AUC KW-3902 /AUC M1 . All data are expressed as meansϮS.D. Statistical significance was estimated by using the Student's t-test or the Aspin-Welch test for independence. p values of less than 0.05 were considered statistically significant. Blood Components Binding An aliquot of heparinized rat blood (5 ml) was incubated with KW-3902 in each formulation at a concentration of 1 mg/ml blood at 37°C for 30 min. After incubation, the blood sample was centrifuged at 3000 rpm for 10 min at 10°C. Blood cell fractions were washed twice with saline and then KW-3902 was extracted with isopropyl alcohol. Plasma was fractionated by ultracentrifugation.
33) The density (d) of the plasma was adjusted to 1.006, 1.063 or 1.210 g/ml by adding a solution containing appropriate amounts of NaCl and NaBr. Each sample (200 ml) in duplicate was centrifuged at 40000 rpm for 3 h at 10°C (CP100a, HITACHI, Tokyo, Japan) using a PRL42T rotor (HITACHI, Tokyo, Japan). A 100-ml aliquot was collected from the uppermost layer of each tube, and then mixed with isopropyl alcohol. The concentration of KW-3902 in each fraction was determined by HPLC on a Shim-pack LCL-ODS column (5 mm, 150ϫ6 mm, Shimadzu Corporation, Kyoto, Japan). The mobile phase consisted of a mixture of acetonitrile and 0.02 mol/l potassium dihydrogenphosphate at 13 : 7 (v/v) delivered at a flow rate of 1.0 ml/min. A UV detector operated at 280 nm was used to detect and quantitate KW-3902. The sample floated at 1.006 g/ml was regarded as the fraction of chylomicron (CM) and very lowdensity lipoprotein (VLDL); that at 1.063 g/ml was regarded as CM, VLDL and low-density lipoprotein (LDL); and that at 1.210 g/ml was regarded as CM, VLDL, LDL and highdensity lipoprotein (HDL). The residues precipitated at 1.210 g/ml were defined as heavier proteins, which are lipoprotein deficient plasma fraction including glycoprotein and albumin. The amounts of KW-3902 in each fractions of heavier proteins, HDL, LDL and the combined fraction of CM and VLDL were calculated by successive subtraction.
Emulsion Fractionation Using the ultracentrifugation method described above but with saline instead of rat plasma, KW-3902 in the lipid emulsion or liposome was fractionated. The sample that floated at 1.006 g/ml was regarded as a fraction of the lipid emulsion. A denser fraction corresponding to the density range of 1.006-1.063 g/ml was liposome or liposome-like vesicles. Figure 2 shows electron micrographs of the lipid emulsion of KW-3902 obtained using the negative-staining method. The diameter of the emulsion particles was about 120 nm consistent with the results of the light scattering analysis (Fig. 2a) . Figure 2b shows the liposome-like vesicles in the emulsion. Partial lipid lamellae were found. The diameter of the liposomes was about 80 nm.
RESULTS

Electron Microscopy
Plasma Concentration and Tissue Distribution To define the effect of the dispersed systems on the pharmacokinetics of KW-3902, we studied the plasma levels and tissue distribution of KW-3902 after i.v. injection of em-KW-3902 (Table 1) , lipo-KW-3902 (Table 1) or solution (free-KW-3902), which is a solution of KW-3902 dissolved in saline containing 1% (v/v) dimethyl sulfoxide and 1% (v/v) 1 N NaOH (KW-3902: 0.1 mg/ml). The plasma levels of M1 were also monitored after injection. Figure 3 shows the plasma concentration-time profiles of KW-3902 and M1 after intravenous injection at 0.1 mg/kg and 1 mg/kg as a lipid emulsion or solution and 1 mg/kg as a liposome. After injection of free-KW-3902, unchanged KW-3902 rapidly decreased in the plasma, and plasma levels of M1 increased after that. Pharmacokinetic parameters of these compounds are summarized in Tables 2 and 3 . The parameters (T 1/2 , CL, MRT and V dss ) of KW-3902 were not significantly different between the two doses used, although AUC 0-ϱ at a 1 mg/kg dose was 7.8 times that at a 0.1 mg/kg dose. Moreover, the parameters (T 1/2 and MRT) of M1 were also not significantly different between the two doses used, and the C max and AUC 0-ϱ at a 1 mg/kg dose were 8.2 and 10.1 times that at a 0.1 mg/kg dose, respectively. It was also found that there was no significant difference in MR between the two doses used. Consequently, the linear elimination of KW-3902 was observed at doses used. Pharmacokinetic parameters after injection of em-KW-3902 or lipo-KW-3902 are also listed in Tables 2  and 3 . The parameters (T 1/2 , AUC 0-ϱ , CL, MRT and V dss for KW-3902 and C max , T 1/2 , AUC 0-ϱ and MRT for M1) of these formulations were not significantly different from the free-KW-3902.
The levels of KW-3902 in the liver were rapidly decreased after injection, the same tendency as for the plasma levels (Fig. 4) . Figure 5 shows the distribution of KW-3902 at 10 min after injection of free-KW-3902 and em-KW-3902. After injection of free-KW-3902, more of the compound (about 8%) was taken up in the liver than any other organ. The distribution of em-KW-3902 was identical to that of free-KW-3902 exception the lung. When injected as a solu- tion, KW-3902 was taken up in the lung in an amount that was about 1% of the dose, and this was significantly higher than that with em-KW-3902 (Fig. 5, pϽ0 .05).
Incubation with Rat Blood
The association of KW-3902 with rat blood components was studied by ultracentrifugation. The distributions of KW-3902 between blood fractions obtained after in vitro spiking of rat blood with free-KW-3902, em-KW-3902 or lipo-KW-3902 are presented in Table 4 . The concentrations of KW-3902 spiked in rat blood were 1 mg/ml. In the case of free-KW-3902, the amounts recovered from the fractions of blood cells, heavier proteins, HDL, LDL, and the combination of CM and VLDL were 12.7, 50.2, 31.9, 2.7 and 2.5%, respectively (Table 4) . After incubation with em-KW-3902, the distribution of KW-3902 in the blood components was similar to that with free-KW-3902. In contrast, considerable amounts of KW-3902 were recovered from the fractions of CM and VLDL (8.2%) after incubation with lipo-KW-3902. The density of the liposome was 1.006ϹdϽ1.063 and analogous to that of LDL and the density of the lipid emulsion was analogous to that of CM and VLDL (dϽ1.006, Table 5 ). The fraction of 1.006Ϲ dϽ1.063 appeared in em-KW-3902 would correspond to the liposome-like vesicles, which were observed in the electron microscopy ( Table 5 ). (pH 7) Water for injection A sufficient quantity A sufficient quantity to make 1 ml to make 1 ml 
DISCUSSION
In a previous paper, 22) we reported the development of a lipid emulsion of KW-3902, a compound that is lipophilic (partition coefficient: log Pϭ4.7) and water-insoluble (solubility is less than 1 mg/ml). Lipid emulsions have been employed as carriers for lipophilic drugs with some clinical success. 5, 6, 13, 14) However, RES readily takes up the oil droplets of conventional lipid emulsions, [23] [24] [25] the carrier potentials of which are reported to be low. 34) By the way, it has been shown that the liposome-like vesicles in commercial parenteral emulsions coexist with typical oil in water emulsions in which the structure of the core oil particles coated in a lipid monolayer. [35] [36] [37] [38] Férézou et al. 37) reported that the amount of liposome-like mesophase increased with the phospholipid/triacylglycerol (PL/TG) ratio. The PL/TG ratio of commercial 10, 20 and 30% fat formulas is 12, 6 and 4%, respectively. In contrast, em-KW-3902 has a large amount of egg lecithin, the mixing ratio of PL to oil being 1 : 1, to give a mean particle size of 130 nm. 22) It is highly likely that liposome-like vesicles would exist in this lipid emulsion. Therefore, we performed a structural analysis of the lipid emulsion. The presence of liposome-like vesicles was confirmed by electron microscopy (Fig. 2b) . These vesicles were about 80 nm in size, which is consistent with the findings of Férézou 37) and Rotenberg. 35) Previous studies reported that liposomes show different pharmacokinetics from emulsions. 23, 39) This would be explained by difference in the affinity for a series of apolipoproteins [40] [41] [42] [43] [44] [45] in blood or the subsequent metabolism by the lipoprotein lipase. 37, [46] [47] [48] Since it has become apparent that a considerable amount of liposome-like fractions exist in lipid emulsion suspensions, we compared the pharmacokinetics and protein binding ability of em-KW-3902 or lipo-KW-3902 with that of free-KW-3902 directly. Em-KW-3902 showed the similar pharmacokinetic profile of free-KW-3902 (Fig. 3) and it would be considered as a intrinsic pharmacokinetics of KW-3902 after injection in rats at 0.1 and 1 mg/kg, which are considered effective doses of KW-3902. 20, 21) The amount of KW-3902 taken up by liver was about 8% of the dose at 10 min after injection irrespective of the dosage form (Figs. 4, 5 ). Liu and Liu studied the liver accumulation of the conventional lipid emulsion using a radiolabeled marker, and found that more than 70% of the emulsion was captured by liver at 6 h after injection in mice. 49) We also previously reported that more than 70% of a dose of a-tocopherol was accumulated in the liver 2 h after the injection of an emulsion with a similar composition to that of the present study. 23) However, in this case the levels of KW-3902 in the liver were rapidly decreased after injection, and the amount of KW-3902 taken up by liver was very low comparing with the these studies. Considering these results, it could be said that KW-3902 dissociated from the oil droplets quickly and completely in circulation after injection. In contrast, the level of KW-3902 in lung was significantly high after injection of free-KW-3902 (Fig. 5, pϽ0.05 ). This would be the result of precipitation of KW-3902 in circula- tion after injection of free-KW-3902. In this respect, the lipid emulsion formulation has an advantage. The blood component binding experiment showed that KW-3902 was released from the lipid emulsion or liposome by binding to the blood cells or plasma proteins, since KW-3902 in lipid emulsion or liposome has not retained in the original density fractions of its carrier after incubation with rat blood (Tables 4, 5 ). Takino et al. investigated the physicochemical interactions between drugs and formulations using four radiolabeled lipophilic compounds to develop long-circulating emulsion carrier systems. 50) In their study, lipophilic drugs with a low log P were rapidly released from oil droplets by dilution after injection, and highly lipophilic drugs with log P values larger than 9 were required to achieve a stable incorporation into the emulsion carrier. Considering that the retaining ability of drugs in the oil droplets would be dependent on their lipophilicities, it could be said that the actual driving force behind the partitioning of KW-3902 away from the lipid emulsion or liposome was the proportional distribution into blood components and the total amount of KW-3902 retained in the oil droplets would be dependant on the ratio of the volume of oil phase to blood volume. In this study, KW-3902 is rapidly distributed to the blood cells or plasma proteins and the lipid emulsion or liposome simply acts as a solvent for KW-3902, which is defined in this report as a vehicle for dissolving the drugs to prepare the injection. In contrast, it could be said that KW-3902 would be retained in the vehicle when highly dosed, i.e., high amount of oily phase was injected relative to the blood volume, and then the lipid emulsion would act as a carrier, which is defined as a vehicle for drug targeting. In this case, RES would capture the more amount of KW-3902 through the vehicles. Consequently, em-KW-3902, which coexists with the liposome-like vesicles in its formulation, would show the intrinsic pharmacokinetics of KW-3902 rather than that of the lipid emulsion or liposome at the expected effective dose. The findings from the present study would provide useful information on the application of lipid emulsion as an injectable formulation of lipophilic agents in vivo.
In summary, the present study demonstrated that the lipid emulsion formulation of KW-3902 simply acts as a solvent and em-KW-3902 shows the intrinsic pharmacokinetic parameters of free-KW-3902. Additionally, lipid emulsion formulation prevented the precipitation of KW-3902 after i.v. injection. These results suggest that KW-3902 as a lipid emulsion formulation will play an important role in clinical medicine.
